Yousry A Ammar

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Molecular Docking

Oxide Nanoparticles

Breast Cancer Cells

Structure Activity Relationship

Top Venues

Drug development research

Chemical biology & drug design

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Hamdy Khamees Thabet, Ahmed Ragab, Mohd Imran, Mohamed Hamdy Helal, Saleh Ibrahim Alaqel, Ahmed Alshehri, Abida Ash Mohd, Saleh Saad Alshammari, Yousry A Ammar, Moustafa S Abusaif
Innovation of 6-sulfonamide-2 H -chromene derivatives as antidiabetic agents targeting α-amylase, α-glycosidase, and PPAR-γ inhibitors with in silico molecular docking simulation. RSC advances 14 (22) (2024)
Hamdy Khamees Thabet, Ahmed Ragab, Mohd Imran, Mohamed Hamdy Helal, Saleh Ibrahim Alaqel, Ahmed Alshehri, Abida Ash Mohd, Saleh Saad Alshammari, Yousry A Ammar, Moustafa S Abusaif
Innovation of 6-sulfonamide-2 H -chromene derivatives as antidiabetic agents targeting α-amylase, α-glycosidase, and PPAR-γ inhibitors with in silico molecular docking simulation. RSC advances 14 (22) (2024)
Ahmed Ragab, Mohamed A Salem, Yousry A Ammar, Wael Mahmoud Kamel Aboulthana, Mohamed H Helal, Moustafa S Abusaif
Explore new quinoxaline pharmacophore tethered sulfonamide fragments as in vitro α-glucosidase, α-amylase, and acetylcholinesterase inhibitors with ADMET and molecular modeling simulation. Drug development research 85 (4) (2024)
Mostafa A Ismail, Moustafa S Abusaif, Mohamed S A El-Gaby, Yousry A Ammar, Ahmed Ragab
A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5- b ]quinoxaline derivatives hybrid with a sulfonamide moiety. RSC advances 13 (18) (2023)
Mostafa A Ismail, Moustafa S Abusaif, Mohamed S A El-Gaby, Yousry A Ammar, Ahmed Ragab
A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5- b ]quinoxaline derivatives hybrid with a sulfonamide moiety. RSC advances 13 (18) (2023)
Samar A El-Kalyoubi, Ahmed Ragab, Ola A Abu Ali, Yousry A Ammar, Mohamed G Seadawy, Aya A Saeed, Eman A Fayed
One-Pot Synthesis and Molecular Modeling Studies of New Bioactive Spiro-Oxindoles Based on Uracil Derivatives as SARS-CoV-2 Inhibitors Targeting RNA Polymerase and Spike Glycoprotein. Pharmaceuticals (Basel, Switzerland) 15 (3) (2022)
Ahmed Ragab, Moustafa S Abusaif, Dina S Aboul-Magd, Mohammed M S Wassel, Gameel A M Elhagali, Yousry A Ammar
A new exploration toward adamantane derivatives as potential anti-MDR agents: Design, synthesis, antimicrobial, and radiosterilization activity as potential topoisomerase IV and DNA gyrase inhibitors. Drug development research 83 (6) (2022)
Yousry A Ammar, Jehan A Micky, Dina S Aboul-Magd, Sondos M A Abd El-Hafez, Sadia A Hessein, Abeer M Ali, Ahmed Ragab
Development and radiosterilization of new hydrazono-quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study. Chemical biology & drug design (2022)
Radwa Ayman, A M Radwan, Amira M Elmetwally, Yousry A Ammar, Ahmed Ragab
Discovery of novel pyrazole and pyrazolo[1,5-a]pyrimidine derivatives as cyclooxygenase inhibitors (COX-1 and COX-2) using molecular modeling simulation. Archiv der Pharmazie (2022)